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Background: Gallstone disease is associated with p.D19H of ABCG8 as well as alterations of cholesterol and bile
acid metabolism. However, molecular mechanisms have not been fully elucidated. It is important to understand the
link between the sterol transporters ABCG5/8 and NPC1L1 and intestinal cholesterol absorption as well as de novo
synthesis in gallstone patients stratified according to 19H risk allele. Moreover, the functional importance of the 19H
variant on intestinal ABCG8 feature remains to be clarified.
Methods: Measurements of serum surrogate markers of cholesterol absorption (plant sterols: sitosterol, campesterol)
and synthesis (cholesterol precursor: lathosterol) were carried out by gas chromatography/mass spectrometry (GC/MS).
For expression studies, total RNA was isolated from 168 ileal biopsies of study participants with (34) and without
gallstone disease (134). Messenger RNA was measured by LightCycler real-time PCR. Genomic DNA was obtained from
blood leukocytes. Genotype frequencies of p.D19H were established using MALDI-TOF mass spectrometry.
Results: Compared to controls, cholesterol absorption but not synthesis in gallstone carriers was diminished by about
21% based on low serum sitosterol (P = 0.0269) and campesterol (P = 0.0231) to cholesterol ratios. D19H was found to
be significantly associated with gallstones (odds ratio [OR] = 2.9, P = 0.0220, 95% confidence interval [CI]:1.22-6.89),
particularly in the overweight cohort (OR = 3.2, P = 0.0430, 95% CI:1.07-9.26). Cholesterol absorption was about 24%
lower in individuals carrying p.D19H compared to wild type (Psitosterol = 0.0080, Pcampesterol = 0.0206). Moreover,
irrespective of phenotype, carriers of p.D19H displayed a significant lower absorption than carriers of the major allele.
The most pronounced effect on cholesterol absorption ratio was observed for serum campesterol levels (wild type
controls to mutated controls 28%, P = 0.0347 and wild type controls to gallstone carriers with 19H allele 37%, P =
0.0030). Notably, ABCG5/8 and NPC1L1 expression was similar in gallstone carriers and controls regardless of p.D19H
presence.
Conclusions: Both gallstone disease and p.D19H of ABCG8 are associated with diminished cholesterol absorption.
However, p.D19H is not responsible for the differences in small intestinal sterol transporter expression.Background
Gallstone disease is a frequent health problem affecting
10-20% of the Western population [1]. An imbalance be-
tween cholesterol, bile acids and phospholipids is a key
factor for cholesterol gallstone formation [2] but the meta-
bolic cause of this disturbance is still unclear. Gallstone
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reproduction in any medium, provided the orlesterol and bile acid homeostasis [3,4]. In the presence of
normal dietary cholesterol its absorption tended to be
diminished in gallstone carriers whereas synthesis was
induced [3]. However, the contribution of newly synthe-
sized to biliary cholesterol in animals and man is small
[5-8] and the origin of excess biliary cholesterol remains
uncertain. Moreover, gallstone carriers respond to an
increased cholesterol load with an elevated biliary choles-
terol secretion and exhibit a diminished hepatic de novo
cholesterol synthesis [3]. Furthermore, the regulation of
cholesterol synthesis in overweight persons, prone to
develop gallstones, differs from the lean individuals and is
feedback inhibited after the application of long-term highLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion in the primary bile acid pool size, an increase of the
biliary fraction of secondary bile acids, reduced gallbladder
motility as well as a prolonged intestinal transit time
[10,11]. The mechanism behind the low primary bile acids
in bile may be a diminished expression of bile acid trans-
porters in the terminal ileum [12,13]. The ultimate conse-
quence is cholesterol supersaturation in the gallbladder
bile, leading to crystal precipitation of free cholesterol and
gallstone formation [2,3,10,14].
Responsible for cholesterol transport in the human gut
are the heterodimeric ATP-binding cassette transporter
(ABCG5/8) and Niemann-PickC1-Like 1 Protein (NPC1L1).
Following incorporation into micelles, dietary as well as
biliary cholesterol is available for uptake from the intes-
tinal lumen through the importer NPC1L1 [15]. This pro-
tein is localized at the apical membrane of the enterocytes
[16] and contributes to intestinal cholesterol homeostasis
[15-18]. The heterodimeric sterol transporter ABCG5/8
determines hepatobiliary cholesterol secretion and choles-
terol efflux out of the enterocytes back into the intestinal
lumen, thereby promoting net cholesterol removal from
the body [19-21]. Moreover, the intestinal cholesterol
transporters are under the transcriptional control of liver
X receptors (LRXα/β), sterol regulatory element-binding
protein (SREBP2), hepatocyte nuclear factors (HNF1α/4α)
and peroxisome proliferator-activated receptor (PPARδ)
[18,22-25].
Human and murine studies support a strong genetic
background of gallstone risk [26-28]. Most prominently
associated with gallstone disease is the D19H polymorph-
ism of the ABCG8 gene [29]. In healthy individuals, the
D19H polymorphism was associated with low cholesterol
absorption [30]. Similarly, Gylling described low serum
total cholesterol and cholesterol absorption in the cohort
of mildly to moderately hypercholesterolemic subjects
with the 19H allele [31]. Recently, the study of Krawczyk
showed that cholesterol absorption was significantly lower
and de novo synthesis higher in gallstone carriers [4] but
this was independent of the D19H polymorphism.
The present study therefore addressed the following
questions: i) are both, low cholesterol absorption and
increased de novo cholesterol synthesis indeed common in
gallstone carriers, ii) is the expression of intestinal choles-
terol transporters and their transcription factors different
in gallstone carriers, iii) does the D19H polymorphism of
the ABCG8 gene affect any of these parameters?
Methods
Ethics statement
The local ethics committee (ethics committee of the Uni-
versity Hospital of Tuebingen and University Tuebingen)
approved this study and all subjects gave written informed
consent prior to participation.Subjects
Study subjects were recruited from the contingent of indi-
viduals invited to undergo routine colonoscopy according
to the recommendations of German Health Organisation
and for cancer prevention. Individuals, who agreed the
participation in the study, were personally interviewed
and seen by the physicians regarding their health condi-
tions. Subjects included in this study had a) normal serum
lipid values and no history of taking lipid-lowering drugs
or drugs interfering with bile acid uptake, b) no known
medical conditions affecting lipid metabolism, c) normal
liver function and no signs of haemolysis or other condi-
tions associated with pigment stones, d) no intestinal sur-
gery and e) no impaired nutritional status. None of the
gallstone carriers or controls had symptomatic gallstone
disease, abnormal liver function, elevated serum lipids or
inflammation in the ileum. Biopsies and blood samples
were collected from a total of 168 individuals in the Robert
Bosch Hospital in Stuttgart. Blood samples (3–5 mL) were
used for cholesterol and phytosterol measurements as well
as for genotyping investigations. Up to eight ileal biopsy
specimens were taken from each participant (for this inves-
tigation two separate samples, each about 8–10 mg, were
used). 134 subjects were healthy controls and 34 indivi-
duals had gallstones. The presence or absence of gallstones
was confirmed by ultrasound. Serum triglycerides and
cholesterol levels were analysed by standard clinical tests.
Measurements of sterol synthesis and absorption
Measurements of the non-cholesterol sterols lathosterol,
campesterol and sitosterol from serum samples were car-
ried out by GC-MS as reported previously [32]. Cholesterol
absorption was given as ratio of sitosterol or campesterol
to total cholesterol and cholesterol synthesis was calculated
as the ratio of lathosterol to cholesterol [33].
Real-time quantitative reverse transcription – polymerase
chain reaction (RT-PCR)
Total RNA was isolated from whole biopsy specimen using
TRIzol extraction procedure (Invitrogen) according to the
manufacturer’s protocol. The integrity, quality and quantity
of RNA were analysed by gel electrophoresis and absorp-
tion measurement. Four hundred ng of total RNA was
reverse transcribed using the (AMV)-reverse transcriptase
system (Promega) and random hexamers. RT-PCR was
performed with LightCycler sequence detection system
(Roche Diagnostics) as reported previously [12,13]. Primer
sequences used for amplification of human ABCG5, ABCG8,
NPC1L1, LXRα, LXRβ, HNF1α, HNF4α, PPARδ and
SREBP2 are listed in Table 1. Target specific PCR con-
ditions were: 95°C for 5 min, 40 cycles at 95°C for 10 s,
followed by 60°C for 5 s, then 72°C for 7 s. For the quanti-
fication of NPC1L1 a PCR of 50 cycles was necessary. At
the end of the PCR, a dissociation curve was performed.
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the second derivative maximum method according to
manufacturer’s instructions. Gene-specific plasmids served
as control templates with specific oligonucleotide primer
pairs. All measurements were carried out in duplicate.
Plasmid construct
Plasmids were constructed with the TOPO TA Cloning
Kit (Invitrogen) according to manufacturer’s recommen-
dations. Four μL PCR product were subcloned into the
EcoRI sites of a 2.1 TOPO TA cloning vector. Trans-
formation was performed with two μl of the ligation
onset to TOP 10 cells (E. coli) and spread to agar plates
appended with X-Gal and ampicillin. The sample was
incubated overnight at 37°C. White colonies were picked
and purified/isolated with the Miniprep kit (Qiagen).
The positive clones were verified by DNA sequencing.
Western blot analysis
For protein analysis a separate whole ileal mucosal bi-
opsy was required. Total protein was isolated using TRI-
zol Reagent (Invitrogen). Protein concentration was
determined applying the Bradford assay (Bio-Rad). Sam-
ples were heated at 95°C for 5 min. A total of six μg for
ABCG8 and 15 μg for ABCG5/NPC1L1 protein were
loaded and then electrophoresed (90 min, 100 V) on
self-cast SDS-PAGE gels (ABCG5/8 10%, NPC1L1 8%)
and blotted on nitrocellulose (0.45 μm, Whatman). After
blotting, membranes were blocked for 1 h with 5% non-
fat dry-milk (NFDM) in Tris-buffered saline containingTable 1 Primer sequences used for QRT-PCR
Fragment Primer Sequen
Exon 9/10 ABCG5 F 5’ – CG
ABCG5 R 5’ – AG
Exon 10/11 ABCG8 F 5’ – GTG
ABCG8 R 5’ – CTG
Exon 17/18 NPC1L1 F 5’ – GTG
NPC1L1 R 5’ – AA
Exon 4/5 LXRα F 5’ – TCA
LXRα R 5’ – TCA
Exon 7/8 LXRβ F 5’ – TAA
LXRβ R 5’ – ACT
Exon 8/10 HNF1α F 5’ – CAC
HNF1α R 5’ – CCA
Exon 9/10 HNF4α F 5’ – ATG
HNF4α R 5’ – TTC
Exon 4/5 SREB2 F 5’ – CAG
SREB2 R 5’ – CTT
Exon 4/5 PPARδ F 5’ – ATG
PPARδ R 5’ – GC0.1% Tween 20 (TBST). Hereafter, membranes were in-
cubated overnight with primary antibodies (ABGC5:
ab45279/Abcam diluted 1:1,000 in 3% NFDM/TBST and
1% of RotiW-Block reagent (Roth); ABCG8: NB400-110/
Novus Biologicals diluted 1:3,000 in 5% NFDM/TBST
and NPC1L1:EPR5717/ab124801/Abcam diluted 1:200
in 3% NFDM/TBST). After being washed five times for
5 min blots were probed with the secondary antibody,
peroxidise-conjugated goat anti-rabbit IgG (1:10,000,
Dianova) and exposed to a chemiluminescent reagent
(SuperSignalT West Dura; Pierce). The immunoreactive
band was obtained at the predicted size of 75 kDa repre-
senting ABCG5 or ABCG8 and 145 kDa representing
the NPC1L1 monomer. Bands were photographed and
immunoquantitation was accomplished by densitometric
analysis using the software AIDA (Raytest). To account
for variability in the amounts of enterocytes in biopsy
specimens, villin contents of all samples were deter-
mined. Therefore membranes were incubated with a pri-
mary antibody against human villin (1:2,000, Chemicon
International), followed by incubation with the second-
ary peroxidise-conjugated anti-mouse IgG antibody
(1:1,500, Oncogene). Protein staining was obtained at
the predicted size of 95 kDa. All measurements were
carried out in duplicate.Isolation of DNA
Genomic DNA was extracted from peripheral blood leu-
kocytes by standard methods using the Qiagen systemce Product size
CGTAGGTCTCCTTTACCA – 3’ 152
TGCATAGGCCAGCATCAT – 3’
GCTGGTGGTCTTCTGTT – 3’ 84
AAGAAGGAGGCCATGTG – 3’
GGGCATCAGTTACAATG – 3’ 166
ACACCGCACTTCCCATAG – 3’
GGCGGATCTGTTCTTCT – 3’ 213
GGCGGATCTGTTCTTCT – 3’
GCAAGTGCCTGGTTTCC – 3’ 200
CGAAGATGGGGTTGATG – 3’
GCCCACCAAGCAGGTCT – 3’ 165
GGCTGCTGGAGGACACTG – 3’
CTTCCGGGCTGGC – 3’ 235
GAGTGCTGATCCG – 3’
CCTCAGATCATCAAGACA – 3’ 202
TCTCTTGCCCCATCATTA – 3’
GAGCAGCCACAGGAGGAAGCC – 3’ 200
ATGAGGCCCCGTCACAGC – 3’
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Prep) according to manufacturer’s recommendations.
Genotyping
The D19H SNP analysis of ABCG8 was performed with
blood DNA using matrix-assisted laser desorption/ioni-
zation time-of-flight mass spectrometry (MALDI-TOF MS)
of allele specific primer extension products as reported pre-






For quality control no-template controls in all plates
and repeated analysis of 10% of randomly selected sam-
ples were performed.
Statistics
For statistical analysis GraphPad Prism version 5 was
used (GraphPad Software, San Diego, Ca, USA). Clinical
characteristics of study participants and all data are pre-
sented as means ± standard error of the mean (SEM).
Differences between groups (anthropometric and metabolic
characteristics (age, body mass index (BMI), total choles-
terol and total triglycerides), cholesterol absorption and
synthesis ratios and all expression data) were investigated
using the two-tailed Mann–Whitney U-test. All correlations
(of expression values as well as of cholesterol absorption
and synthesis ratios) between variables were analysed with
Spearman’s correlation rank test. Observed and expected
genotype frequencies within the study population were
compared by means of Hardy–Weinberg equilibrium calcu-
lations [35]. Data were considered in Hardy–WeinbergTable 2 Anthropometric and metabolic characteristics of the
Total
Parameter Controls Gallstone carriers
Number 134 34
Age (years) 57 ± 1.1 61 ± 1.9
BMI (kg/m2) 25.2 ± 0.3 26.6 ± 0.6α
Total cholesterol (mg/dL) 214 ± 3.7 207 ± 6.2
Total triglycerides (mg/dL) 121 ± 6.1 126 ± 7.8
Lathosterol:Cholesterol (μg/mg) 1.15 ± 0.06 1.33 ± 0.15η
Sitosterol:Cholesterol (μg/mg) 1.23 ± 0.06 0.97 ± 0.08β
Campesterol:Cholesterol (μg/mg) 1.47 ± 0.07 1.16 ± 0.11γ
BMI = body mass index.
Values are given as means ± SEM (standard error of the mean).
Significance between the controls and gallstone carriers was analysed with Mann–W
Normal weight subgroup is defined as BMI ≤ 25.4, overweight subgroup as BMI > 25
P-values <0.05 were considered as statistical significant.
Controls vs. gallstone carriers: αP = 0.0378, βP = 0.0269 (21%), γP = 0.0231 (21%), η (1
Normal weight persons vs. overweight individuals: δP = 0.0028 after adjustment (fac
adjustment P = 0.039.equilibrium when P-values were >0.05. Statistical analysis
of genotype frequency differences between gallstone car-
riers and controls was done using two-sided Fisher’s exact
test as appropriate. Odds ratios (ORs) together with a 95%
confidence interval (CI) are given as risk measures for the
development of gallstones. All statistical tests were two-
tailed and a P-value of <0.05 was considered as statistically
significant.
Results
Characteristics of the study cohort
Several relevant anthropometric and metabolic charac-
teristics (age, serum cholesterol and triglyceride levels)
of the participants did not differ significantly and are
summarized in Table 2. Therefore, the total study cohort
was stratified in two weight groups. The calculation of
anthropometric data reveal a mean age of 57 years in
the control group and 61 years in the gallstone carrier
group. As weight also depends on age [36-40], in the
present study the normal weight group was defined as
BMI ≤ 25.4, individuals with BMI > 25.4 were regarded as
overweight. Since the percentage of overweight subjects
was higher among gallstone carriers (68%) than among
control individuals (44%), the mean body mass index was
slightly higher in the gallstone group (BMI = 26.6) com-
pared to controls (BMI = 25.2) (P = 0.0378).
Cholesterol absorption and synthesis in gallstone disease
Cholesterol absorption based on the serum sitosterol/chol-
esterol ratio correlated well with the campesterol/choles-
terol ratio (ρ = 0.90, P < 0.0001, Spearman’s rank test).
Interestingly, in the total cohort including both weight
groups, cholesterol absorption was significantly lower by
about 21% in gallstone carriers compared to controlsStuttgart study cohort
Normal weight Overweight
Controls Gallstone carriers Controls Gallstone carriers
75 11 59 23
55 ± 1.5 63 ± 3.6 59 ± 1.4 60 ± 2.3
22.7 ± 0.3 23.3 ± 0.6 28.4 ± 0.4 28.2 ± 0.6
211 ± 4.7 214 ± 6.3 217 ± 6.0 203 ± 8.8
101 ± 6.8 125 ± 14.2 143 ± 9.9 127 ± 9.5
0.99 ± 0.07 1.22 ± 0.26 1.33 ± 0.09δ 1.39 ± 0.18
1.36 ± 0.09 1.11 ± 0.19 1.06 ± 0.07ε 0.90 ± 0.06
1.67 ± 0.12 1.23 ± 0.24 1.24 ± 0.08ζ 1.12 ± 0.11
hitney U-test (nonparametric, two-tailed).
.4.
6%). No adjustment in the total group.
tor 6) P = 0.0168, εP = 0.0044 after adjustment P = 0.0264, ζP = 0.0065 after
Figure 1 Expression of cholesterol transporters in female
gallstone carriers and healthy controls. The expression analysis
was performed in human ileal mucosal biopsies. Values are
calculated as means ± SEM (standard error of the mean). Significance
between the controls and gallstone carriers was analysed with
Mann–Whitney U-test (nonparametric, two-tailed). Normal weight
subgroup is defined as BMI≤ 25.4, overweight subgroup as BMI >
25.4. P-values <0.05 were considered as statistically significant. (A-C)
Quantification of mRNA expression is given as transcript numbers.
ABCG5/ABCG8 = ATP-binding cassette transporter, NPC1L1 =
Niemann-Pick C1-Like 1 protein *P = 0.0417, C = control subject,
GS = gallstone carrier. Total: C = 98, GS = 30; normal weight: C = 57,
GS = 10; overweight: C = 41, GS = 20. (D) Representative Western blot
images of ABCG8, ABCG5 and NPC1L1 in ileal mucosa of gallstone
carriers and controls. Protein content was determined by
densitometric analysis. The data were normalized to villin, an
epithelial marker protein. ABCG8: C = 70, GS = 20; ABCG5: C = 7,
GS = 7; NPC1L1: C = 7, GS = 7.
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The correlation between hepatic cholesterol synthesis and
intestinal absorption was inverse and statistically significant
(sitosterol/lathosterol ρ = −0.43, P < 0.0001; campesterol/
lathosterol ρ = −0.38, P < 0.0001, Spearman’s rank test). In
principle, these results were similar in female and male
subpopulations when analysed separately, as shown in
Additional file 1: Table S1C and D.
Overweight controls exhibited a higher synthesis
(+33% P = 0.0028) and lower absorption (sitosterol −22%
P = 0.0044; campesterol −26% P = 0.0065) rate than nor-
mal weight persons. Remarkably, in the subgroups the
rate of cholesterol synthesis tended to be higher (4-22%, ns)
and of cholesterol absorption lower (on average ~17%, ns)
in gallstone individuals than in controls. However, none of
these differences between gallstone carriers and controls
were statistically significant.Ileal expression of sterol transporters and their relevant
transcription factors in gallstone disease
Next, the ileal expression patterns of the three relevant
sterol transporters ABCG8, ABCG5 and NPC1L1 were
analysed (Figure 1). Regarding sterol exporter ABCG8 and
ABCG5, no significant changes in expression were apparent
when stratified according to gallstones (Figure 1A and B),
also not within the different weight groups. In comparison
with the exporters detailed above, ileal expression of the
NPC1L1 importer was rather low (Figure 1C). Only normal
weight stone-carriers exhibited a reduced expression by
80% compared to respective controls (P = 0.0417), whereas
all other groups showed no relevant and significant ex-
pression differences. As shown in Figure 1D, comparable
expression patterns could be stated on protein levels. The
correlation analyses by Spearman’s rank test between trans-
porters showed the following moderate to small correlation
coefficients: ABCG5/ABCG8 ρ = 0.50, P < 0.0001; ABCG5/
Table 3 Mean values of mRNA transcript expression in ileal mucosa of important transcription factors in gallstone
carriers and healthy controls
Transcripts/10 ng mRNA
Total Normal weight Overweight
Group Controls Gallstone carriers Controls Gallstone carriers Controls Gallstone carriers
Target (Mean ± SEM) (n = 95) (n = 29) (n = 55) (n = 9) (n = 40) (n = 20)
LXRα 70261 ± 4308 70004 ± 6774 75035 ± 6026 63318 ± 12203 63853 ± 5964 73544 ± 8245
LXRβ 36208 ± 2570 37337 ± 5445 39285 ± 3445 30067 ± 6295 32361 ± 3821 40781 ± 7426
HNF1α 5282 ± 362 7037 ± 864 5555 ± 488 5814 ± 953 4944 ± 542 7616 ± 1183a
HNF4α 48814 ± 3407 53086 ± 10701 51632 ± 4561 45244 ± 9990 44939 ± 5115 56615 ± 14955
PPARδ 7326 ± 574 7985 ± 999 7540 ± 806 6821 ± 1468 7060 ± 817 8537 ± 1304
SREBP2 29807 ± 2223 30681 ± 3864 31373 ± 3068 30677 ± 5749 27928 ± 3236 30683 ± 5145
Values are given as means ± SEM (standard error of the mean). Significance between the controls and gallstone carriers was analysed with Mann–Whitney U test
(nonparametric, two-tailed). P-values <0.05 were considered as statistical significant.
LXR = liver X receptors, HNF = hepatocyte nuclear factor, PPAR = peroxisome proliferator-activated receptor, SREBP = sterol regulatory element-binding protein.
α P = 0.0470 after adjustment (factor 6) P = 0.282.
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Furthermore, it was investigated whether gallstone dis-
ease is associated with alterations in the major regulatory
transcription factors of the sterol transporters as summar-
ized in Table 3. Only for HNF1α an increased transcript ex-
pression was observed in overweight gallstone carriers
compared to relevant controls (P = 0.0470). None of the
other regulatory factors exhibited any significant expression
difference between controls and gallstone carriers in gen-
eral, also not in the different weight groups. Finally, no clear
expression correlation of the transcription factors to their
respective transporters could be stated (data not shown).
Association of D19H polymorphism with cholelithiasis
Since individuals with the D19H polymorphism (rs11887534,
c.52 G > c) in the ABCG8 gene are known to have a higher
risk of developing gallstones [29,41], a genotype analysis of
this polymorphism was performed in our cohort. The
study population was subdivided into weight- and disease-
specific subgroups. Genotype frequencies, odds ratios (ORs)
and 95% confidence intervals (CI) for each subgroup were
calculated to obtain genotype-associated disease risk esti-
mations (Table 4). Moreover, the genotype-associated dis-
ease risk was tested by analysing wild type homozygousTable 4 The frequency of the polymorphism D19H in the gall
Stuttgart
Group Controls (134) Gallst
Genotype G/G G/c c/c G/G
Total 115 19 0 23
Normal weight 66 9 0 9
Overweight 49 10 0 14
G =major allele, c =minor allele, OR = odds ratio, CI = confidence interval.
Statistical analysis of genotype frequency differences between gallstone carriers an
95% confidence interval (CI) are given as risk measures for the development of gall
considered as statistically significant.(GG) individuals compared to the subjects with the hetero-
zygous type (Gc). Confirming prior reports [29,41], D19H
was found to be significantly associated with gallstone dis-
ease in our total population with OR = 2.9 (P = 0.0220, 95%
CI: 1.22–6.89). Notably, overweight simultaneous carriers
of gallstones and p.D19H displayed a higher OR (OR = 3.2,
P = 0.0430, 95% CI: 1.07–9.26) than the respective normal
weight group (OR = 1.6, P = 0.6270, 95% CI: 0.30–8.77).
Influence of the D19H polymorphism on cholesterol
metabolism and intestinal ABCG8 expression
Next, we analysed the effect of the D19H polymorphism
in ABCG8 on cholesterol absorption and cholesterol
synthesis. As shown in Figure 2A and B, carriers of the
D19H gallstone risk allele were characterised by signifi-
cantly reduced intestinal cholesterol absorption of about
24% (sitosterol P = 0.0080, campesterol P = 0.0206).
After stratifying the Stuttgart population into phenotype-
and genotype-specific groups, the influence of the 19H
allele on sterol levels was investigated further (Figure 3).
The level of cholesterol absorption markers was lower by
15–19% in gallstone carriers with the wild type allele than
in the controls (Figure 3A and B). There was no relevant
difference in absorption between gallstone carriers and
controls with the minor allele. However, independent ofstone carriers and controls of the population from
one carriers (34) (GG<>Gc)
G/c c/c P-value OR (95% CI)
11 0 0.022 2.9(CI: 1.216 to 6.889)
2 0 0.627 1.6(CI: 0.303 to 8.770)
9 0 0.043 3.2(CI: 1.071 to 9.264)
d controls was done using Fisher’s exact test. Odds ratios (ORs) together with a
stones. All statistical tests were two-tailed and a P-value of <0.05 was
Figure 2 Influence of the polymorphism D19H on markers of cholesterol metabolism. Cholesterol absorption is calculated as the ratio of
sitosterol or campesterol to cholesterol (A, B), cholesterol synthesis is calculated as the ratio of lathosterol to cholesterol (C). Values are calculated
as means ± SEM. Significance between the wild type individuals and SNP carriers was analysed with Mann–Whitney U-test (nonparametric, two-
tailed). P-values <0.05 were considered as statistically significant. (GG) = wild type individual; (Gc) = carrier of p.D19H; (GG) = 93 and (Gc) = 25.
* P sitosterol = 0.0080, * P campesterol = 0.0206.
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lower in carriers of the Gc variant compared with wild
type. The most pronounced effect on cholesterol absorp-
tion ratio was observed for serum campesterol levels (wild
type controls to mutated controls 28%, P = 0.0347 and wild
type controls to cases with p.D19H 37%, P = 0.0030).
Regarding the cholesterol synthesis marker lathosterol and
serum cholesterol levels, no significant differences
were detected between the genotype/phenotype groups
(Figure 3C and D).
To study whether this polymorphism affected intes-
tinal transporter expression, the intestinal expression of
the ABCG8 gene was related to the D19H subgroups.
Ileal ABCG8 levels, mRNA as well as protein features,
did not differ between controls with and without the
SNP, also not in the gallstone group (Figure 4).
Discussion
The present study was performed to assess the role of
cholesterol metabolism and intestinal transporters as
related to the ABCG8 19H risk allele in gallstone disease.
Four major observations were made: first, cholesterol
absorption was decreased in gallstone carriers but chol-
esterol synthesis was not significantly different between
individuals with gallstones and controls. Second, the ileal
expression of the sterol transporters ABGG5, ABCG8
and NPC1L1 as well as of their relevant transcription
factors is similar between gallstone carriers and controls.
Third, in the cohort of gallstone carriers and controls
the D19H polymorphism of the ABCG8 gene was asso-
ciated with a low cholesterol absorption but not with
altered de novo synthesis. Fourth, the ileal expression of
the ABCG8 gene is not influenced by the presence of the
mutated allele 19H.
Cholesterol and bile acid homeostasis are clearly altered
in gallstone patients compared to a healthy population [3].
Most importantly, body weight influences cholesterolabsorption and synthesis [42]. Obesity as well as excessive
dietary fat and cholesterol uptake are common character-
istics in industrial countries and are tightly related to
gallstones [43-46]. Although the combination of multiple
risk factors and mechanisms is known to contribute to the
hypersaturation with cholesterol, the cause for biliary cho-
lesterol hypersecretion is poorly defined. Cholesterol bio-
synthesis, biliary secretion, intestinal absorption and fecal
loss are the major key steps of cholesterol homeostasis but
only absorption and de novo synthesis determine the net
body cholesterol supply. Basically, the absorption effi-
ciency of cholesterol in the small intestine is defined by
the concurrent influx and efflux of intraluminal choles-
terol molecules crossing the apical membrane [47].
Studies in the murine model with deletion of the
ABCG8 gene observed increased intestinal sterol absorp-
tion and reduced hepatic cholesterol secretion [48]. In
contrast, overexpression of ABCG5/8 in mice promotes
biliary cholesterol secretion and reduces fractional absorp-
tion of dietary cholesterol [20]. On the other hand, high
cholesterol absorption efficiency and rapid biliary secre-
tion of chylomicron remnant cholesterol enhance chole-
lithogenesis in gallstone-susceptible mice [49]. Enhanced
hepatic expression of ABCG5/8 was already described in
Chinese stone-carriers [50] and further studies provide
evidence for the functional relevance of hepatic ABCG5/8
expression in relation to the biliary cholesterol secretion
[20,51,52].
Measurements of the cholesterol precursor lathosterol
allow indirect estimation of de novo cholesterol synthesis
and the determination of plant sterols (sitosterol and
campesterol) reflects intestinal cholesterol uptake [32,33].
Using this technique our findings are clearly consistent
with the observation that cholesterol synthesis is generally
higher in overweight persons and the efficiency of choles-
terol absorption is reduced [43,46]. Moreover, in the
current study a diminished cholesterol absorption ratio
Figure 3 Influence of the polymorphism D19H on markers of cholesterol metabolism in gallstone disease. Cholesterol absorption is
calculated as the ratio of sitosterol or campesterol to cholesterol (A, B), cholesterol synthesis is calculated as the ratio of lathosterol to cholesterol
(C), total serum cholesterol levels mg/dL (D). Values are calculated as means ± SEM. Significance between wild type individuals and SNP carriers
was analysed with Mann–Whitney U-test (nonparametric, two-tailed). P-values <0.05 were considered as statistically significant. C = control subject,
GS = gallstone carrier. GG genotype (wild type individual): C = 75, GS = 14; Gc genotype (carrier of p.D19H): C = 18, GS = 11.
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is in line with previous studies using either the isotope
ratio method [3] or also serum surrogate markers [4].
However, there are controversial data regarding choles-
terol de novo synthesis. The earlier studies found a de-
creased cholesterol synthesis in gallstone carriers (with
high deoxycholate in bile) [11], whereas Kern found an
increased synthesis [3]. In the recent study of Krawczyk
reduced intestinal absorption concurred with a (possibly
compensatory) enhanced hepatic cholesterol de novo synthesis[4]. However, in the present study the low intestinal chol-
esterol absorption was not coupled with enhanced hepatic
de novo synthesis in gallstone carriers.
Looking for the possible mechanisms determining chol-
esterol absorption in the gut, the expression of ABCG8,
ABCG5 and NPC1L1 as the key intestinal sterol transpor-
ters in humans was analysed. Regarding sterol exporter
ABCG8 and ABCG5, no significant changes in expression
were apparent, also not within the different weight groups.
In line with the observation of Masson [53], the levels of
Figure 4 Correlation of ABCG8 expression to the frequency of
the polymorphism D19H in the Stuttgart cohort. The expression
analysis was performed in human ileal mucosal biopsies. Values are
given as means ± SEM. Significance between the subgroups was
analysed with Mann–Whitney U-test (nonparametric, two-tailed).
P-values <0.05 were considered as statistically significant. (A)
Quantitative analysis of mRNA expression is calculated as copy
numbers. (GG) = wild type individual; (Gc) = carrier of p.D19H.
Controls: (GG) = 80 and (Gc) = 15; gallstone carriers: (GG) = 20 and
(Gc) = 9. (B) Representative Western blot images of ABCG8 protein
and villin in ileal mucosa of control individuals and gallstone carriers,
with and without p.D19H. Protein content was determined by
densitometric analysis. The data were normalized to villin, an
epithelial marker protein. Controls: (GG) = 59 and (Gc) = 11; gallstone
carriers: (GG) = 11 and (Gc) = 9.
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in our study. Both proteins have different distribution pro-
files along the intestine and can exhibit variable trans-
porter conformations with each other [54]. Recently, a
Chinese study demonstrated an increased intestinal ex-
pression of NPC1L1 in gallstone patients as a mechanism
for upregulated cholesterol absorption in the small intes-
tine [55]. A decreased hepatic NPC1L1 down-regulation
in normal weight female gallstone carriers was already
described by Cui [56]. The highest expression levels of thetransporter were determined in the jejunum [16] which is
not easily accessible.
The polymorphism D19H of sterol exporter ABCG8 was
associated with gallstones in various populations and differ-
ent ethnic groups [29,41,57-61]. In line with prior observa-
tions the association with gallstones was confirmed in our
population. However, overweight carriers of the ABCG8
19H risk allele displayed a higher OR than normal weight
gallstone carriers. Obesity, of course, doubles the gallstone
risk and strengthens the metabolic regulatory differences in
cholesterol and bile acid homeostasis [3,9,44,46]. In con-
trast to the study of Srivastava [59], the D19H relative risk
was more pronounced in males than in females (Additional
file 1: Table S2). This is probably due to a strong effect from
the male overweight gallstone group.
Despite these descriptive studies about the relationship
of D19H to the abnormalities in the lipid profile or to
gallstones [29,41,62,63], there are no direct cell culture
studies on the functional influence of the polymorphism
on transporter expression or activity so far. Most prior
data, however, are compatible with a gain-of-function
hypothesis of the 19H allele contributing to the choles-
terol supersaturation of bile and the formation of choles-
terol gallstones [27,29]. In our study carriers of p.D19H
were characterised by significantly reduced intestinal chol-
esterol absorption irrespective of the presence or absence
of gallstones and the polymorphism did not affect intes-
tinal ABCG8 expression. These results are compatible
with the findings of Berge [30] in a normal non-gallstone
cohort and those of Gylling showing that hypercholestero-
lemic carriers of the 19H allele exhibited reduced choles-
terol absorption as well [31]. Since ABCG5/G8 are sterol
exporters, a gain-of-function would lead to diminished ab-
sorption with excessive amounts of cholesterol secreted
into intestine as well as bile [29,31,41]. It is unclear why in
other cohorts [4] there was no association between the
19H risk allele and intestinal cholesterol absorption and
also not with gallstones.
Conclusions
In summary, both the presence of gallstones and the
ABCG8 polymorphism D19H were related to diminished
cholesterol absorption but the polymorphism did not
affect ileal expression of ABCG8, suggesting a gain-of
-function of the mutated transporter. Since cholesterol ab-
sorption was also low in gallstone carriers without this
polymorphism, this genetic trait does not fully explain this
characteristic of gallstone disease.
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